Document is current
Any future updates will be listed below
-
Authors
Han, Xuexiang https://orcid.org/0000-0003-0011-5222
Alameh, Mohamad-Gabriel https://orcid.org/0000-0002-5672-6930
Xu, Ying
Palanki, Rohan
El-Mayta, Rakan https://orcid.org/0000-0002-5855-233X
Dwivedi, Garima
Swingle, Kelsey L. https://orcid.org/0000-0001-8475-9206
Xu, Junchao https://orcid.org/0000-0003-0725-8111
Gong, Ningqiang https://orcid.org/0000-0002-9444-8505
Xue, Lulu https://orcid.org/0000-0001-5719-1336
Shi, Qiangqiang
Yoon, Il-Chul
Warzecha, Claude C. https://orcid.org/0000-0002-3659-2867
Wilson, James M. https://orcid.org/0000-0002-9630-3131
Weissman, Drew https://orcid.org/0000-0002-1501-6510
Mitchell, Michael J. https://orcid.org/0000-0002-3628-2244
-
Funding
Funding for this research was provided by:
US National Institutes of Health (NIH) Director's New Innovator Award
- License Information
-
More Information
Article History
Received: 7 September 2023
Accepted: 21 September 2024
First Online: 22 November 2024
Competing interests
: X.H. and M.J.M. have filed a patent application based on this work. J.M.W. is a paid advisor to and holds equity in iECURE, Passage Bio, and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies and Ceva Santé Animale. He has sponsored research agreements with Alexion Pharmaceuticals, Amicus Therapeutics, CBM, Ceva Santé Animale, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE, and Passage Bio, which are licensees of Penn technology. J.M.W. and C.C.W. are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. The other authors declare no competing interests.
